Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Adagrasib + RMC-4630 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Adagrasib | Krazati | MRTX849|MRTX-849|MRTX 849 | KRAS G12C inhibitor 33 | Krazati (adagrasib) covalently binds to and stabilizes GDP-bound KRAS G12C, thereby preventing KRAS downstream signaling and potentially inhibiting tumor growth (PMID: 31658955). Krazati (adagrasib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy (FDA.gov). |
RMC-4630 | RMC-4630-02|SAR442720|SAR 442720 | SHP2 Inhibitor 20 | RMC-4630 is an inhibitor of SHP2 (PTPN11) that prevents MAPK signaling and cell growth (PMID: 31727671). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04418661 | Phase Ib/II | Pembrolizumab + RMC-4630 Adagrasib + RMC-4630 | Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies | Terminated | USA | NLD | ESP | AUS | 4 |